Precigen 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Precigen reported Q3 2026 total revenue of $74.1 million, including $72.9 million in Papsimios net product revenue, up approximately $20 million, or 37%, from Q2.
- Launch-to-date Papsimios revenue through the end of Q3 was approximately $151 million; more than 500 patients had begun treatment and more than 300 had completed treatment.
- Precigen reported Q3 net income of $35.8 million and net income of $47.9 million for the 9-month period ended September 30th, 2026.
- The company generated $11.9 million in cash from operating activities in Q3 and ended September with $51 million in cash, cash equivalents, and investments, up from $38.7 million at the end of June.
- Q3 costs of products and services were $6.5 million, producing a gross margin of $67.6 million, or 91%; R&D costs were $6.6 million and SG&A expenses were $22.4 million.
- Precigen reported $2.7 million in net other expense, including $3 million of interest expense on $100 million of outstanding debt, offset by approximately $300,000 of investment interest income.
- The company had 96% of $6.5 million in trade accounts receivable on its balance sheet and access to an additional $25 million under its debt facility.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
This call is being recorded on Wednesday, November 4, 2026. I would now like to turn the conference over to Steve Harasym.
Please go ahead. Thank you, operator, and thank you to everyone joining us for Precigen's third quarter 2026 financial results and business update call.
Joining me today are Helen Sabzevari, our President and Chief Executive Officer, Phil Tennant, our Chief Commercial Officer, Harry Thomasian, our Chief Financial Officer, and Rutul Shah, our Chief Operating Officer. Helen will begin with our business highlights, Phil will review commercial progress, and Harry will discuss our financial results for the quarter. Rutul will be available for Q&A as well. Before we begin, I remind everyone that today's discussion will include forward-looking statements based on our current expectations and beliefs. Actual results could differ materially because of risks and uncertainties described in the forward-looking statement slide of this presentation and our most recent SEC filings. With that, I will turn the call over to Dr. Sabzevari.
Helen? Thank you, Steve, and thank you to everyone joining us today.
The third quarter of 2026 represents another defining milestone for Precigen. Just over one year ago, we made history with the FDA approval of PAPZIMEOS, the first approved treatment for adults with recurrent respiratory papillomatosis, or RRP, in more than a century of this disease. Today, we are demonstrating what that achievement means for patients, physicians, and our business. We have moved rapidly from regulatory approval to commercial success, delivering three consecutive quarters of significant revenue growth, bringing PAPZIMEOS to major medical centers, infusion centers, and community practices across the country, achieving profitability in both the second and third quarters, and generating positive cash flow in the third quarter, ahead of our guidance, bringing in net product revenue in Q3 of $72.9 million and the launch to date of $151 million. This is the definition of execution excellence.
These accomplishments reflect our paradigm-shifting approach to drug development, combining differentiated science, a smart indication selection, and innovative clinical and regulatory strategies to accelerate the delivery of transformative therapies to patients. With the recent conditional approval of a competitor therapy for RRP treatment, I want to provide perspective on Precigen's position and the continued opportunity ahead. We have always anticipated competition and incorporated it into our strategic planning, commercial modeling, and investment decisions from the outset. Our strategy was built not simply to be first, but to establish enduring leadership in RRP, and that is exactly what we have accomplished. Our leadership is built on four pillars: the first-line product defined by its efficacy, safety, durability, and the ease of administration, a strong regulatory foundation, an established commercial infrastructure, and a demonstrated ability to execute.
Together, these attributes have already established our position in the market, and they continue to strengthen our value proposition. First, our product. The true measure of any successful therapy is the benefit it delivers to patients. The pivotal clinical study of PAPZIMEOS demonstrated an unmatched 51% complete response rate, with 18 of 35 patients requiring no surgeries during the 12 months following treatment completion. The 51% complete response primary efficacy endpoint, which is reflected in the PAPZIMEOS FDA-approved prescribing information, sets a new clinical benchmark in RRP. Similarly, PAPZIMEOS is unmatched in establishing a meaningful standard of durable complete responses for up to five years without the need for any additional treatment. Being free of surgeries for a sustained period speaks for itself in its groundbreaking clinical benefit, which differentiates PAPZIMEOS by a wide margin. In the pivotal clinical study, PAPZIMEOS demonstrated a well-characterized safety profile.
with no dose-limiting toxicities and no treatment-related adverse events greater than grade 2, which is another point of differentiation. Equally important is the practicality of treatment. PAPZIMEOS is administered through a defined regimen of subcutaneous injections without the need for an external specialized device, which could also introduce device-related adverse events. Importantly, leading RRP experts continue to recognize and adopt PAPZIMEOS as the first-line standard of care treatment for adults with RRP. Second, our regulatory foundation. One of the most achievements in our development of PAPZIMEOS was securing full FDA approval in August 2025 based on the strength of the efficacy and the safety evidence presented in our BLA. This was full approval without the requirement for a post-approval confirmatory clinical trial to verify the clinical benefit. That is a significant achievement.
Confirmatory clinical trials can require years of additional development, substantial financial investment, and continued regulatory uncertainty, including the risk of FDA revocation. Our approved indication, the treatment of all adults with RRP, is broad, without the requirement for a minimum number of prior surgeries, enabling physicians to consider treatment based on each patient's clinical needs. This full regulatory approval, combined with our clinical evidence and broad label indication, creates a secure regulatory foundation for PAPZIMEOS. Third, our commercial leadership. Being first to market gave us an important opportunity. Our commercial strategy and execution have transformed that opportunity into a significant first-mover advantage. The results speak for itself. As of today's call, well over 500 patients have begun treatment of PAPZIMEOS, and well over 300 of them have completed treatment.
This rapid adoption in a rare disease is a powerful demonstration of the demand for PAPZIMEOS and the effectiveness of our commercial strategy. Phil will provide more details on these subjects, but we have established our leadership position in RRP, and we continue to rapidly scale our commercial business. Finally, our ability to execute. Precigen achieved full FDA approval of PAPZIMEOS in less than five years from IND, demonstrating our ability to translate innovative science into an approved medicine with remarkable speed. We have demonstrated our ability to execute across the entire development and commercialization continuum, from innovative science to regulatory approval to a growing, profitable commercial business. Today, with more than a year of commercial experience, a strong physician adoption, and enthusiastic market reception, we have substantially strengthened that position to sustain and grow our significant first-mover advantage.
With that, I will turn the call over to Phil for a closer look at our commercial progress.
Phil? Thank you, Helen. What an extraordinary year it has been for PAPZIMEOS.
Just over one year after FDA approval, we have moved beyond the foundational phase of our launch and established PAPZIMEOS as the first-line standard of care for adults with RRP. We have activated treatment centers across the country, secured broad payer coverage, and established the infrastructure to support treatment in major academic centers, infusion centers, and community practices. Our commercial strategy is delivering results, and the pace of adoption demonstrates the strong demand for PAPZIMEOS. Third quarter PAPZIMEOS net product revenue reached $72.9 million, bringing launch-to-date revenues through the end of Q3 to approximately $151 million. These results demonstrate the strength of our launch and the significant momentum we are carrying into the fourth quarter. I want to highlight four areas that illustrate the scale of our achievement and the opportunity ahead. First, patient adoption. As mentioned earlier, well over 500 patients have begun treatment of PAPZIMEOS, and well over 300 of them have completed treatment.
Having spent decades leading oncology and specialty product launches around the world, I believe the speed of adoption we have achieved in just over one year is exceptional, particularly in a rare disease historically managed through repeated surgeries. Importantly, PAPZIMEOS is being prescribed across the spectrum of disease severity. A significant proportion of patients treated to date had fewer than three surgeries in the preceding 12 months. This demonstrates that physicians are embracing the broad PAPZIMEOS label and integrating treatment into their approach to managing RRP, rather than waiting until patients have undergone repeated surgical interventions. We now also have well over 600 patients registered in our hub, reflecting continued patient engagement and demand. Importantly, as I've said previously, hub registrations do not capture all patients receiving treatment.
Increasingly, experienced institutions are independently managing patient access and reimbursement through their own established processes. This reflects the success of our efforts to integrate PAPZIMEOS into their clinical workflows without the need for specialized administration equipment or device-specific training. Treatment centers are not simply adopting PAPZIMEOS; they have built the capabilities to support ongoing prescribing and administration independently. Second, broad market access. We have secured coverage representing over 315 million U.S. lives across commercial plans, Medicare, and Medicaid, establishing broad access to nearly 100% of insured lives nationwide. Our permanent J-code, effective from April 1, 2026, combined with the experienced field reimbursement support and patient assistance resources, provides established pathways from prescription to treatment. We started early to remove many of the traditional access barriers encountered during a specialty product launch, and this helped establish the infrastructure to support continued expansion.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
10 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
